Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...
Eisai and Merck & Co have reported positive data from the LEAP-012 trial for their combination of Lenvima (lenvatinib) and ...
Merck's bumpy six-year relationship with Eisai's anti-cancer medication Lenvima landed on somewhat better footing in Spain ...
Median PFS increased from 10 months with TACE to 14.6 months with the addition of lenvatinib (Lenvima) and pembrolizumab ...
AstraZeneca’s Phase 3 study in bladder cancer, showed that giving Imfinzi — before and after surgery — cut the risk of death.
Intermediate-stage hepatocellular carcinoma remains a challenge to treat. The new findings may lead to a new treatment ...
A combined treatment regimen of lenvatinib (Lenvima), pembrolizumab (Keytruda), and transarterial chemoembolization (TACE) significantly outperformed dual placebo and TACE in improving ...
Patients with intermediate-stage liver cancer may benefit from receiving a Lenvima-Keytruda combination with transarterial ...
Life sciences sector saw a drop in M&A deals in H1 2024, but values increased, with Johnson & Johnson (JNJ) leading the pack ...
The head of NATO’s military committee says that Ukraine has the solid legal and military right to strike deep inside Russia ...
Merck’s (NYSE:MRK) anti-PD-1 therapy Keytruda as part of a combination regimen with Eisai’s (OTCPK:ESALF) (OTCPK:ESAIY) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback